DBV restructuring claims 200 jobs as it beats out a path toward peanut patch OK
Regulatory troubles around its peanut allergy treatment have hurt DBV Technologies bad.
It became even clearer Thursday morning as the French biotech disclosed the scope …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
